Patient with cryptogenic cirrhosis

Main Article Content

Elanaz Alizade
Ali Alizade

Abstract

Cryptogenic cirrhosis is cirrhosis of uncertain etiology, with no definitive clinical and histological criteria for a specific disease. More than half of such patients are women, the average age is about 60, and patients generally have only mild liver enzyme abnormalities. Cryptogenic cirrhosis's pathophysiology is unknown; therefore, further research is required to elucidate the underlying etiology. The problem of liver cirrhosis is extremely important since this pathology occurs mainly in young and healthy people. In patients with cryptogenic cirrhosis, aminotransferase (AST and ALT) levels are usually only mildly elevated or normal. In our case report, a 41-year-old male patient was approved to the emergency department due to migraine pain. Liver enzymes were high in the blood analysis taken from the patient. As a result of the liver ultrasound carried out on the patient, it was reported to have decreased liver size and irregular boundaries and compatible with chronic liver disease. The patient used various analgesics due to migraine in his 20s. However, no cause could be identified for the patient's liver failure.

Downloads

Download data is not yet available.

Article Details

How to Cite
Alizade, E., & Alizade, A. (2024). Patient with cryptogenic cirrhosis. Annals of Innovation in Medicine, 2(3). https://doi.org/10.59652/aim.v2i3.238
Section
Case Studies

References

Horlenko OM, Kossey GB, Pushkarenko OA, Prylypko LB. LIVER CIRRHOSIS WITH CRYPTOGENIC GENESES. CLIN-ICAL CASE. Wiad Lek.

Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease.

Caldwell S. Cryptogenic cirrhosis: what are we missing? Curr Gastroenterol Rep.

Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther.

Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology

Arner P, et al. Adipose lipid turnover and long-term changes in body weight. Nat.

Patel N, Sharma B, Samant H. Cryptogenic Cirrhosis. 2023 Feb 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Pub-lishing;

Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis.